# Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

> **NCT00949949** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 38 (actual)

## Conditions studied

- Cholangiocarcinoma of the Gallbladder
- Localized Gallbladder Cancer
- Unresectable Gallbladder Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** everolimus
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00949949
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949949, "Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00949949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*